HEPATIQ Granted Patent, Exhibiting at DDW & SNMMI

By: PRLog
IRVINE, Calif. - Dec. 30, 2015 - PRLog -- HEPATIQ® LLC announced that they have been granted U.S. Patent 9,155,513 titled “Systems and Methods for Determining Hepatic Function from Liver Scans”. This patented technology is used by the company’s software program, HEPATIQ, to process nuclear medicine liver-spleen images.

The HEPATIQ software calculates PHM™, which precisely measures liver function. PHM was proven to be an accurate predictor of clinical outcomes in the National Institutes of Health (NIH) sponsored multi-center HALT-C trial.

The company will be exhibiting HEPATIQ at the Digestive Diseases Week (DDW) Conference in May 2016 and the Society of Nuclear Medicine & Molecular Imaging (SNMMI) Conference in June 2016.

“We are delighted to receive a strong U.S. patent for our technology in only 15 months since filing the application,” said Dipu Ghosh, Co-Founder and CEO of HEPATIQ LLC (http://www.hepatiq.com/). “With this important asset secured, we look forward to expanding operations and promoting the product at leading medical conferences and exhibitions.”

“The PHM measure of hepatic function correlates closely with the functional mass of the liver which determines what happens to patients, including complications of chronic liver disease and tolerance of surgery,” said Dr. John Hoefs, Co-Founder and COO of HEPATIQ LLC (http://www.hepatiq.com/). “Hepatic fibrosis, by contrast, is less important as the correlation with hepatic function is indirect and not at all precise,” concluded Dr. Hoefs.

HEPATIQ LLC (http://www.hepatiq.com/) is focused on diagnosing the severity of liver disease and predicting adverse clinical outcomes. Chronic liver disease is a slow and silent killer. It is widespread with about 15% prevalence globally. About 32,000 people die each year in the US from liver disease. For more information, please visit www.hepatiq.com (http://www.hepatiq.com/).

Disclaimer

This press release contains forward-looking statements. These are based on current expectations and beliefs and are subject to numerous risks, uncertainties and change. The parties disclaim any obligation to update any forward-looking statement as a result of developments occurring after this release.

Contact
Dipu Ghosh, CEO
***@hepatiq.com

Photos: (Click photo to enlarge)

HEPATIQ LLC Logo

Read Full Story - HEPATIQ Granted Patent, Exhibiting at DDW & SNMMI | More news from this source

Press release distribution by PRLog

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.